Cenegermin

Cenegermin
Names
Trade namesOxervate
Other namesCenegermin-bkbj, recombinant human nerve growth factor (rhNGF), human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer)[1]
Clinical data
Drug classNerve growth factor[2]
Main usesNeurotrophic keratitis[3]
Side effectsEye pain, increased tear production, eyelid pain[3]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • AU: B3
  • US: N (Not classified yet)
    Routes of
    use    		Eye drop
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa619001
    Legal
    License data
    Legal status
    • AU: S4 (Prescription only)
    • US: ℞-only
    • EU: Rx-only
    Chemical and physical data
    FormulaC583H908N166O173S8
    Molar mass13267.15 g·mol−1

    Cenegermin, sold under the brand name Oxervate, is a medication used to treat neurotrophic keratitis.[3] It is used in those with moderate or severe disease.[3] Use was not recommended by the United Kingdom.[2] It is used as an eye drop.[4]

    Common side effects include eye pain, increased tear production, and eyelid pain.[3] Safety in pregnancy is unclear.[2] It is a recombinant form of nerve growth factor (NGF).[2]

    Cenegermin was approved for medical use in Europe in 2017 and the United States in 2018.[3][4] In the United States 14 vials costs about 23,600 USD as of 2021.[5]

    Medical uses

    Dosage

    It is used as 1 drop in the affected eye every 2 hours, 6 times per day.[3] It is used for 8 weeks.[3]

    History

    It was developed by Anabasis Pharma, Dompé Farmaceutici, and Ospedale San Raffaele.[6]

    The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7]

    Research

    In addition to neurotrophic keratitis, cenegermin is also under development for the treatment of dry eyes, retinitis pigmentosa, and glaucoma.[6]

    See also

    References

    1. ↑ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1): 76. hdl:10665/330984.
    2. 1 2 3 4 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1210. ISBN 978-0857114105.
    3. 1 2 3 4 5 6 7 8 "Oxervate". Archived from the original on 31 October 2020. Retrieved 2 January 2022.
    4. 1 2 "Cenegermin-bkbj Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 2 January 2022.
    5. ↑ "Oxervate Prices and Oxervate Coupons - GoodRx". GoodRx. Retrieved 2 January 2022.
    6. 1 2 "Cenegermin - Dompe Farmaceutici - AdisInsight". adisinsight.springer.com. Archived from the original on 2020-06-05. Retrieved 2020-06-05.
    7. ↑ New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Archived from the original on 17 September 2020. Retrieved 16 September 2020.
    External sites:
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.